Oncolytics Biotech Reports Data in Colorectal Cancer Study

By Karen Roman

Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to the 4–6 months historical benchmarks.

The company is enrolling patients for its Phase 2 study to evaluate pelareorep combined with FOLFIRI and bevacizumab, and is in conversations with the FDA for a potential accelerated approval pathway, it stated.

“We believe these data demonstrate a compelling durability signal for pelareorep in colorectal cancer,” said Jared Kelly, Oncolytics CEO. “We believe these results support a path toward accelerated approval in second-line RAS-mutant MSS metastatic colorectal cancer.”

READ MORE

Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment

Never Miss our Weekly Highlights HERE

Contact:

IPO Edge

www.IPO-Edge.com

[email protected]

Click HERE to follow us on LinkedIn

View Comments